Last updated: February 23, 2026
What is NDC 65038-0286?
NDC 65038-0286 refers to Nivolumab (Opdivo), 240 mg. It is an immune checkpoint inhibitor approved for multiple oncology indications, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and others.
Market Overview
Current Market Size and Growth
The global immune checkpoint inhibitor market was valued at approximately USD 20 billion in 2022. Nivolumab accounts for a substantial share within this market. The rise in prevalence of cancers treatable by immunotherapy and expanding indications have driven growth.
Key market drivers:
- Increasing cancer incidence globally, especially NSCLC and melanoma.
- Broadened approvals for multiple indications.
- Preference for immunotherapy over chemotherapy in first-line treatment in many cancers.
- Competitive landscape includes pembrolizumab (Keytruda), atezolizumab ( Tecentriq), and durvalumab (Imfinzi).
Market Segmentation
| Segment |
Key Data |
| Indications |
Melanoma, NSCLC, renal cell carcinoma, Hodgkin lymphoma, others |
| Estimated US Market (2022) |
USD 7.5 billion |
| Major Competitors |
Pembrolizumab (Keytruda), Atezolizumab (Tecentriq), Durvalumab (Imfinzi) |
| Pricing for Nivolumab (240 mg) |
USD 4,600–4,800 per 240 mg dose in United States |
Competitive Positioning
Nivolumab holds significant market share due to early approval and robust efficacy data. Its dosing regimen of 240 mg every 2 weeks or 480 mg every 4 weeks provides convenience.
Price Trends and Projections
Current Pricing Landscape
- US: USD 4,600–4,800 per 240 mg vial. Slight variations occur across providers and payers.
- Europe: Prices range from EUR 3,800 to EUR 4,200 (~ USD 4,200–4,700, based on exchange rates), reflecting similar high-cost positioning.
- Other Markets: Pricing varies based on local formulary negotiations and reimbursement policies.
Factors Influencing Future Pricing
- Patent protection expiration: No immediate patent fatigue expected until at least 2028.
- Biosimilar emergence: Potential biosimilar competition could reduce prices by 20–40% over five years.
- Manufacturing costs: Stable, given established production processes.
- Regulatory and reimbursement environment: Tightening policies in some regions could apply downward pressure.
Price Projection (Next 5 Years)
| Year |
Expected Price Range (USD per 240 mg) |
Key Factors |
| 2023 |
USD 4,600–4,800 |
Market stability; no biosimilar competition |
| 2024 |
USD 4,400–4,700 |
Cost reductions from further manufacturing efficiencies |
| 2025 |
USD 4,200–4,600 |
Introduction of biosimilars in select markets |
| 2026 |
USD 4,000–4,500 |
Increased biosimilar competition; price pressure |
| 2027 |
USD 3,800–4,200 |
Biosimilar availability; regulatory reevaluation |
Revenue Impact
Decreases in drug prices could lead to revenue declines unless offsets occur through increased volume or expanded indications. The current revenue estimate for Nivolumab exceeds USD 7 billion annually in the US alone.
Policy and Regulatory Impact
- Patent expiries expected around 2028 for core indications.
- Biosimilar approvals in the US, EU, and Japan expected post-2024, which may impact pricing.
- Pricing regulations: Certain countries implement price caps or negotiate discounts, impacting projections.
Summary
- Nivolumab (NDC 65038-0286) remains a high-value immunotherapy with a stable pricing structure in the US, roughly USD 4,600–4,800 per 240 mg.
- Market growth driven by expanding indications and patient access.
- Price decline projections based on biosimilar competition suggest a 15–20% reduction over five years.
- Revenue stability depends on volume growth, indication expansion, and regulatory environment.
Key Takeaways
- The drug maintains premium pricing in the current market.
- Future price reductions are probable due to biosimilar competition and policy pressures.
- Market share remains solid but could decline with increased biosimilar adoption.
- Pricing strategies should align with biosimilar market entry timelines.
- Volume growth and indication expansion are critical to offset potential revenue declines.
FAQs
Q1: When might biosimilars for nivolumab enter the US market?
A1: Biosimilar approval is anticipated post-2024, with market entry likely by 2025–2026.
Q2: How does the emergence of biosimilars affect pricing?
A2: Biosimilars typically reduce prices by 20–40%, impacting branded drug revenues.
Q3: Are there upcoming indications that could influence Nivolumab’s market share?
A3: Yes, ongoing trials for additional cancers could expand the market and justify sustained or increased prices.
Q4: Will regulatory changes impact the future price of nivolumab?
A4: Potentially. Price caps or reimbursement reforms could lower prices, especially in Europe and low-income markets.
Q5: What is the potential for demand growth in emerging markets?
A5: Increasing cancer prevalence and expanding reimbursement could boost demand, offsetting price declines.
References
[1] MarketWatch. (2022). Immunotherapy market size.
[2] IQVIA. (2022). Oncology market data.
[3] FDA. (2022). Biosimilar approvals.
[4] European Commission. (2022). Drug pricing policies.
